Source comparison
MK-677 Dosing: Research Protocol Comparison
10mg daily 30–40% above baseline Minimal osteocalcin elevation (<10%) No significant DEXA change in published trials Minimal appetite increase, rare glucose elevation Insufficient for bone anabolic effect. IGF-1 rises but does not reach threshold for osteoblas
This comparison does not assign a generated winner or score.
- 10mg daily
- 30–40% above baseline
- Minimal osteocalcin elevation (<10%)
- No significant DEXA change in published trials
- Minimal appetite increase, rare glucose elevation
- Insufficient for bone anabolic effect. IGF-1 rises but does not reach threshold for osteoblast activation
- 25mg daily
- 60–90% above baseline
- Osteocalcin increase 20–40%, CTX stable or reduced
- Lumbar spine +1.8–2.7%, femoral neck +1.2–1.9%
- Moderate appetite increase, transient edema, fasting glucose +4–8 mg/dL
- Standard dose in all major bone density trials. Consistent anabolic response with manageable side effects
- 50mg daily
- 100–120% above baseline
- Osteocalcin increase 40–60%, but higher GH side effects limit adherence
- No additional BMD benefit vs 25mg in head-to-head comparison
- Significant glucose elevation (+10–18 mg/dL), persistent edema, sleep disruption
- No evidence of superior bone outcomes. Higher GH-mediated effects without proportional efficacy gain